Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fianlimab and Cemiplimab in Combination With Chemotherapy in Resectable Early Stage NSCLC
NCT06161441Phase 2Active, not recruiting
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Jul 2024
- Primary completion
- Aug 2026
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 12
01
Overview
A Phase 2 trial of fianlimab in non-small cell lung cancer (NSCLC), sponsored by Regeneron Pharmaceuticals. Started Jul 2024; status: active, not recruiting.
02
Drugs
fianlimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06161441.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06161441.